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Abstract
Background: Osteosarcoma is the most prevalent primary malignant bone tumor, but treatment is difficult and
prognosis remains poor. Recently, large-dose chemotherapy has been shown to improve outcome but this
approach can cause many side effects. Minimizing the dose of chemotherapeutic drugs and optimizing their
curative effects is a current goal in the management of osteosarcoma patients.
Methods: In our study, trypan blue dye exclusion assay was performed to investigate the optimal conditions for
the sensitization of osteosarcoma U2OS cells. Cellular uptake of the fluorophores Lucifer Yellow CH dilithium salt
and Calcein was measured by qualitative and quantitative methods. Human MTX ELISA Kit and MTT assay were
used to assess the outcome for osteosarcoma U2OS cells in the present of shock wave and methotrexate. To
explore the mechanism, P2X7 receptor in U2OS cells was detected by immunofluorescence and the extracellular
ATP levels was detected by ATP assay kit. All data were analyzed using SPSS17.0 statistical software. Comparisons
were made with t test between two groups.
Results: Treatment of human osteosarcoma U2OS cells with up to 450 shock wave pulses at 7 kV or up to 200
shock wave pulses at 14 kV had little effect on cell viability. However, this shock wave treatment significantly
promoted the uptake of Calcein and Lucifer Yellow CH by osteosarcoma U2OS cells. Importantly, shock wave
treatment also significantly enhanced the uptake of the chemotherapy drug methotrexate and increased the rate of
methotrexate-induced apoptosis. We found that shock wave treatment increased the extracellular concentration of
ATP and that KN62, an inhibitor of P2X7 receptor reduced the capacity methotrexate-induced apoptosis.
Conclusions: Our results suggest that shock wave treatment promotes methotrexate-induced apoptosis by altering
cell membrane permeability in a P2X7 receptor-dependent manner. Shock wave treatment may thus represent a
possible adjuvant therapy for osteosarcoma.
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Background
Osteosarcoma is the most prevalent primary malignant
bone tumor affecting both adults and children [1] and
accounts for 2.4 % of all pediatric cancers [2]. Osteosar-
coma arises from osteoid tissues [3] and is currently
treated with chemotherapy and surgery [4]. Despite sig-
nificant improvements in the treatment of osteosarcoma
in recent decades, the 5-year survival rate for osteosar-
coma is still only not more than 60 % [5]. Alternative
treatments have also been employed [6, 7]. For example,
Wang et al. reported triazine-modified dendrimer for effi-
cient TRAIL gene therapy in osteosarcoma. In their study,
a triazine-modified dendrimer G5-DAT 66 was synthe-
sized and used as a vector for TRAIL gene therapy in vitro
and in vivo, and their results suggested that triazine-
modified dendrimer has promising potential for TRAIL
gene therapy in osteosarcoma [7]; but these treatments
achieved only marginal improvements in comparison
to conventional chemotherapy. Therefore, conventional
chemotherapy is still the predominant treatment for
osteosarcoma. However, high doses of cytotoxic chemo-
therapy can cause life-threatening side effects, including
cardiotoxicity and nephrotoxicity. Balancing the dose of
chemotherapeutic drugs to reduce side effects and main-
tain the curative efficacy of chemotherapeutics remains a
challenge in the care for osteosarcoma patients.
Recent advances suggest that shock wave treatment
may sensitize osteosarcoma cells to chemotherapeutic
drugs [8]. Shock waves are elicited by a transient pres-
sure disturbance and characterized by high positive pres-
sure. The rapid pressure transition of shock waves exerts
very high tension on exposed surfaces, damaging their
structure [9, 10]. Approximately 20 years ago, extracor-
poreal shock waves were introduced for the treatment of
kidney stones and have substantially improved the
treatment of urolithiasis [11, 12]. Subsequently shock
wave therapy has been adopted for orthopedics and
traumatology to treat various insertional tendinopathies
(enthesiopathies) with delayed unions and nonunions of
fractures and for the treatment of various musculoskeletal
diseases [11, 12]. Shock waves were also reported to en-
hance the cytotoxicity of doxorubicin and methotrexate in
osteosarcoma cell lines [8], suggesting that shock waves
may sensitize osteosarcoma cells to conventional chemo-
therapeutics. However, the mechanisms underlying this
effect remained unknown.
In this study, we treated human osteosarcoma U2OS
cells with methotrexate (MTX) in the presence or absence
of extracorporeal shock waves and assessed cell viability
and membrane permeability. We found that shock waves
enhanced the cytotoxic effect of MTX by increasing cell
membrane permeability through the secretion of ATP and




Human osteosarcoma U2OS cells were obtained from
the Shanghai Institute of Cell Biology (Cell Bank, Chinese
Academy of Sciences, Shanghai, China) and cultured in
Roswell Park Memorial Institute (RPMI)-1640 medium
(HyClone, Beijing, China) supplemented with 1 %
penicillin-streptomycin (HyClone, Beijing, China), 10 %
(vol/vol) fetal bovine serum (HyClone, Beijing, China) in
250 ml culture flasks at 37 °C in an humidified atmos-
phere of 5 % CO2. Once every 4 days, cells were detached
with trypsin/EDTA (HyClone, Beijing, China), counted
and re-seeded at 1 × 106 cells/flask.
Extracorporeal shock waves exposure
Using a model KDE-2001 extracorporeal shock wave
lithotripter (Beijing Zhongke Jian’an Meditechnics,
Beijing, China) shock waves were generated by under-
water spark discharge from an electrode jacketed with
an ultraviolet light (UV)-resistant outer membrane. Cells
were transferred to 1.8 ml polypropylene tubes. The
propagation waves were focused on the center of the
liquid column, located by X-ray. Test tubes were
wrapped in a triple layer of Parafilm and stored in an ice
bath before and after application of shock wave. Using a
generator, 7 kV or 14 kV shock waves were generated
with a capacitance of 0.5 μF and a frequency of 50 Hz.
Cells (1 × 106 cells/ml in 0.25 ml) in a 1.8 ml polypropyl-
ene round-bottom tube were exposed to 0, 50, 100, 150,
200, 250, 300, 350, 400, 450, 500, 1,000, or 1,500 shock
wave pulses at 7 kV or 14 kV. The numbers viable cells
were determined by trypan blue dye exclusion assay
using a hemocytometer. Each condition was repeated in
triplicate in three independent experiments.
Fluorophores
Cellular uptake of the fluorophores Lucifer Yellow CH
dilithium salt (457.25 Da, L0259, λex 428 nm, λem
540 nm) and Calcein (622.53 Da, C0875, λex 470 nm,
λem 509 nm), acquired from Sigma (Saint Louis, MO,
USA), was measured. A Lucifer Yellow CH dilithium salt
(LY) solution (1 mM) was prepared in phosphate-
buffered saline (PBS) without Mg2+ and Ca2+. A Calcein
solution (0.2 mM) was prepared in 1 M NaOH. Living
and damaged cells were distinguished by propidium
iodide (PI) staining. PI (20 μg/ml) was acquired from
Beyotime (Haimen, China) and was added to the cells
for 5 min before capturing fluorescence images under a
fluorescence microscope (λex 535 nm, λem 615 nm;
Olympus, IX51) at 20 °C. An excitation of 428 nm was
used for LY and 470 nm for Calcein. Extracellular fluoro-
phores were removed by washing 3 times with PBS, and
samples were resuspended in PBS. For qualitative detec-
tion, cells were added to 12-well plates preconditioned
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with fibronectin (F8180; Beijing Solarbio Science & Tech-
nology, Beijing, China) to aid attachment. After 30 min,
cells were observed under a microscope. For quantitative
determination, cells were resuspended in 1 ml PBS and
sonicated for 1 min (Model VC × 750, Sonics & Materials).
Then 100 μl of sonicated material was added to a 96-well
black bottom plate and fluorescence was read at 20 °C
with a Thermo Scientific Fluoroskan Ascent FL at an
excitation of 430 nm and an emission of 540 nm for
LY, and an excitation of 460 nm and an emission of
510 nm for Calcein.
MTX assay
MTX was dissolved in DMSO and tri-distilled water and
cells were divided into 4 groups: control group, MTX
group (100 ng/ml MTX), MTX + S1 group (100 ng/ml
MTX 400 7 kV shock waves), MTX+ S2 group (100 ng/ml
MTX, 150 14 kV shock waves). A sample of cells (1 × 106)
from each condition was washed with PBS three times
and intracellular MTX was quantified by Human MTX
ELISA Kit (Shanghai Heng Yuan Biological Technology,
Shanghai, China). The kit uses a biotinylated sandwich
enzyme-linked immunosorbent assay to assess MTX
levels in samples. Briefly, MTX was added to the well
pre-coated with anti-MTX monoclonal antibody, followed
by sequential incubation and addtion of biotinylated
anti-MTX antibody, HRP conjugated streptavidin-
biotin and DAB substrate. The remaining cells (1 × 106)
were cultured for 24 h and viability was assessed by
MTT assay.
Detection of P2X7 in U2OS cells by immunofluorescence
U2OS cells were resuspended in 4 % paraformaldehyde
solution to a density of 1 × 106 cells/ml. Then 5 μl of cell
suspension was dropped on Superfrost plus slides and
incubated at 50 °C for 15 min, followed by incubation at
37 °C for 24 h with 2 μl P2RX7 polyclonal antibody
(11144-1-AP, 1:20, Proteintech, Chicago, IL, USA) in a
humidified atmosphere with 5 % CO2. Slides were
washed three times with PBS, then incubated at 50 °C
for 15 min, followed by incubation for 1 h at 37 °C with
2 μl TRITC-conjugated goat anti-rabbit IgG (H + L)
secondary antibody (SA00007-2, 1:20, Proteintech) in a
humidified atmosphere with 5 % CO2. The slides were
washed in tri-distilled water and observed under fluores-
cence microscope. The control group was incubated with-
out primary antibody.
Detection of extracellular ATP levels
Cells at 70–80 % confluency were resuspended to 2 × 106
cells/ml, and 0.25 ml of cell suspension was added to
1.8 ml of Eppendorf tubes and treated with 400
rounds of shock waves at 7 kV or 150 rounds at
14 kV in the presence or absence of GdCl3 to block
mechanically stimulated ATP channels [13] or Brefeldin A
(BFA) to inhibit vesicular ATP release [13]. Extracellular
ATP concentrations were determined using an ATP assay
kit (Shanghai Heng Yuan Biological Technology) ac-
cording to the manufacturer’s instructions.
MTT assay
Cell viability was determined with a 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay. Cells at 70–80 % confluency were resus-
pended at 2 × 106 cells/ml. Then 100 μl of cell suspension
was added to each well of a 96-well plate and incubated
with ATP (1, 10, 100, 500, or 1000 μM) for 24 h and 20 μl
of 5 mg/ml MTT solution was added to each well and
cells cultured for an additional 4 h. The culture medium
was removed and 150 μl dimethylsulfoxide (DMSO) was
added to dissolve formazan. Cell viability was quantified
by measuring absorbance at 490 nm using a microplate
spectrophotometer to calculate the optical density
(OD) values.
Annexin V-FITC/PI double staining of apoptosis
Cells of 70–80 % confluency were resuspended at 2 × 106
cells/ml, and 0.25 ml of cell suspension was added to a
1.8 ml Eppendorf tube and treated with MTX and ex-
posed to 400 shock wave pulses at 7 kV or 150 shock
wave pulses at 14 kV in the presence or absence of
the P2X7 receptor inhibitor KN62. Then, cell apoptosis
was determined using an AnnexinV-FITC/PI apoptosis
detection kit (Vazyme Biotech, Nanjing, China) according
to the manufacturer’s instructions.
Statistical analysis
All data were analyzed using SPSS17.0 statistical soft-
ware and expressed as mean ± SD. Comparisons were
made with t test between two groups. Group control
data were used as the baseline for statistical comparison
with other groups. A P value of <0.05 was considered
statistically significant.
Results
Effect of shock wave treatment on U2OS cell viability
To investigate optimal conditions for the sensitization of
osteosarcoma cells to chemotherapy, human osteosar-
coma U2OS cells were treated with 0, 50, 100, 150, 200,
250, 300, 350, 400, 450, 500, 1,000 or 1,500 shock wave
pulses at 7 kV or 14 kV. Cell viability was assessed by
trypan blue dye exclusion. We found that viability of
U2OS cells remained >95 % following <450 shock wave
pulses at 7 kV (Fig. 1a) or <200 pulses at 14 kV (Fig. 1b).
Therefore, we subjected cells in subsequent experiments
to 400 shock wave pulses at 7 kV or 150 pulses at 14 kV.
We also treated MC3T3 cells, an osteoblast precursor
cell line with these parameters and found that the
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viability of MC3T3 cells also remained >95 %, suggesting
that this treatment does not harm normal bone cells.
Shock waves stimulate uptake of Calcein and LY
(Lucifer Yellow) by U2OS cells
To determine the effects of shock wave treatment on cell
membrane permeability, U2OS cells were treated with
shock waves as described above in the presence of LY or
Calcein and cellular uptake of LY or Calcein was
assessed by fluorescence microscopy. PI was used to dis-
tinguish between living and dead cells. We found that
neither condition increased the proportion of dead cells
(Fig. 2a and c). Cells treated with Calcein in combination
with shock waves exhibited increased green fluorescence
when compared to cells that were incubated in the ab-
sence of fluorophore or shock waves, or cells incubated
with Calcein alone (Fig. 2b). Similarly, when compared
to cells incubated in the absence of fluorophore or shock
waves or to cells incubated with LY alone, cells treated
with LY in combination with shock waves exhibited in-
creased green fluorescence (Fig. 2d). Quantification of
fluorescence intensity revealed that cells treated with
Calcein followed by 400 shock wave pulses at 7 kV or
150 shock wave pulses at 14 kV exhibited highest fluor-
escence intensity (Fig. 2e) with statistical significance
compared to untreated control (P < 0.05). These results
indicate that shock waves promote cellular uptake of LY
and Calcein with better effects by adding fluorophore
prior to shock waves.
Shock waves promote uptake of MTX and enhance its
cytotoxicity on U2OS cells
Based on the above findings, we explored whether shock
waves can promote cellular uptake of the chemotherapy
drug MTX. We incubated U2OS cells with 100 ng/ml
MTX followed by 400 shock wave pulses at 7 kV or 150
pulses at 14 kV. Then we determined intracellular MTX
concentrations by using a human MTX ELISA assay.
Both shock wave treatments significantly enhanced
MTX uptake with greatest MTX uptake elicited by 150
shock wave pulses at 14 kV (P < 0.05, Fig. 3a). After
treatment, the cells were cultured for 24 h and prolifera-
tion was assessed using an MTT assay. Compared to un-
treated controls, cells treated with MTX showed reduced
viability, which was further reduced by shock wave treat-
ment (P < 0.05, Fig. 3b). These results demonstrate that
shock wave treatment significantly enhances the uptake of
chemotherapy drug MTX and the cytotoxic effect of this
anti-cancer drug on U2OS cells.
Shock wave treatment of U2OS cells increases
extracellular ATP concentrations
To explore the mechanism underlying the enhancement
of MTX uptake by shock wave treatment, we investi-
gated whether ATP release is involved. First, we deter-
mined whether P2X7 receptors are present on the cell
surface of cells using P2X7-specific antibodies. Using im-
mune fluorescence staining, we found strong expression
of P2X7 receptors on the surface of U2OS cells (Fig. 4a).
To assess whether shock waves promote ATP release,
U2OS cells were treated with shock wave treatment as
described above in the presence or absence of the ATP
release inhibitors GdCl3 or Brefeldin A (BFA). Extracel-
lular ATP concentrations were determined using ATP
assay. Both shock wave treatments significantly in-
creased extracellular ATP concentrations (P < 0.05).
Moreover, GdCl3 and BFA alone or in combination re-
duced shock wave-induce release of ATP (Fig. 4b). Al-
though the combination of GdCl3 and BFA reduced
extracellular ATP concentrations, the inhibition was not
significant or complete. This indicates that shock wave
mediated ATP release involves mechanosensitive chan-
nels, vesicular mechanisms, and additional release most
likely due to a third mechanism: the high-strength in-
stant positive phase pressure that is generated by shock
wave during a few seconds may cause a transient in-
crease of cell membrane permeability, leading to a burst
of ATP outflow.
Fig. 1 Determination of the optimal experimental conditions of shock waves for human osteosarcoma U2OS cells. U2OS cells were treated with
the indicated number of shock at the voltage of 7 kV (a) or 14 kV (b). The cell viability was assessed by trypan blue exclusion assay. Data are
mean ± SD, n = 5, *p < 0.05, Student,s t-test
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P2X7 receptor stimulation promotes cell permeability,
MTX uptake, and cytotoxicity of U2OS cells
We sought to determine whether shock waves promote
MTX uptake and cytotoxicity by altering membrane
permeability or by causing apoptosis due to the massive
release ATP and stimulation of P2X7 receptors. We first
treated U2OS cells with ATP and assessed cell viability
using the MTT assay. As shown in Fig. 5a, ATP at
Fig. 2 Shock waves enhanced the uptake of Calcein and LY in U2OS cells. a-b, U2OS cells were stained with Calcein (green) or PI (red) and
treated with shock waves as described. c-d, U2OS cells were treated with LY and subjected to shock waves as indicated. LY (green) or PI (red)
influx was measured. e Cells were treated as described and LY and Calcein influx was assessed. Data are mens ± SD, n = 3, *p < 0.05,Student’s
t-test. **In calcein + S1: addition of calcein prior to shock wave treatment; in S1 + calcein: shock wave treatment prior to addition of calcein.
Same for LY
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concentrations <100 μM did not noticeably affect cell
viability. However, ATP concentrations ≥100 μM signifi-
cantly reduced cell viability (P < 0.05). Considering that
shock wave treatment induced extracellular ATP con-
centrations of only 1.6 μM (Fig. 4b), these results suggest
that ATP release does not contribute to shock wave-
induced cell death by triggering P2X7 receptor-mediated
apoptosis. Instead, these findings suggest that shock
wave treatment opens cell membrane channels that fa-
cilitate MTX uptake. To test this hypothesis, we treated
U2OS cells with MTX in the presence or absence of the
P2X7 receptor inhibitor KN62 and we assessed apoptosis
following shock wave treatment. We found that MTX-
induced apoptosis was significantly weakened by KN62
treatment (P < 0.05, Fig. 5b and c), which indicates that
P2X7 receptors are required for the enhancement by
shock waves of MTX-induced apoptosis. In addition, to
verify the key role for P2X7 receptor in the cell membrane
permeability, we determined the uptake of Calcein and LY
following addition of KN62 and found significantly re-
duced intake of Calcein and LY following addition of
KN62 (Fig. 6). These results suggest that shock wave treat-
ment promoted intake of MTX by altering cell membrane
permeability via P2X7 receptor-ATP signaling, thereby en-
hancing methotrexate-induced apoptosis.
Discussion
In this study, we demonstrated that subjecting cells to
fewer than moderate shock wave treatment does not
cause a significant loss of U2OS cell viability. We found
viability of U2OS cells remained >95 % following <450
shock wave pulses at 7 kV or <200 pulses at 14 kV,
which were used for further experiments. Shock waves
significantly promoted the uptake of fluorophores
Calcein and LY. Moreover, better effects were obtained by
adding fluorophore prior to shock waves, suggesting the
Fig. 3 Shock waves significantly stimulated U2OS cell uptake of chemotherapy drug MTX and enhanced MTX cytotoxicity. a U2OS cells were
treated with 100 ng/ml MTX followed by shock waves of 400 7 kV or 150 14 kV shock waves. Intracellular MTX concentrations were determined
by Human MTX ELISA. b U2OS cells were treated with 100 ng/ml MTX followed by shock waves of voltage of 400 7 kV or 14 kV/150. The cells
were cultured for 24 h and cell proliferation was tested by MTT assay. Data are mean ± SD, n = 3, *p < 0.05, Student,s t-test
Fig. 4 P2X7 was highly expressed on the cell surface and shock waves increased the extracellular concentration of ATP in U2OS cells. a P2X7
receptor expression in U2OS cells. Representative images of anti-P2X7 antibody separate experiments are shown. b Cells treated with BFA, GdCl3,
and shock waves, and extracellular ATP concentrations were assessed in supernatants of the treated cells as indicated. Data are mean ± SD, n = 3,
*p <0.05, Student, s t-test
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shock wave can increase transient cell membrane perme-
ability. More importantly, we also found that shock waves
significantly enhanced the uptake of MTX and the cyto-
toxicity of cells to this chemotherapeutic drug. This find-
ing was consistent with the results by Palmero [8],
however, in their study, the underlying mechanism was
not investigated. We further found that P2X7 was highly
expressed on the surface of U2OS cells and that shock
waves increased the extracellular concentration of ATP. In
addition, we found that ATP had a significant effect on
cell viability with concentrations ≥100 μM only, while the
highest ATP efflux concentration by shock wave was
1.6 μM, indicating that ATP and P2X7 receptors do not
directly induce apoptosis following shock waves. Our data
showed that shock wave treatment enhanced MTX-
induced apoptosis through mechanisms that involve cell
membrane permeability changes mediated by ATP release
and P2X7 receptor stimulation. The proposed mechanism
by which shockwave treatment increases osteosarcoma
cell death is depicted in Fig. 7: shock wave cells induce ef-
flux of intracellular ATP, which binds P2X7 receptors to
increase membrane permeability and influx of MTX into
the cell, ultimately leading to apoptosis. Our findings sug-
gest that shock wave treatment could represent a promis-
ing adjuvant therapy for osteosarcoma.
Since its discovery, shock wave therapy has been
widely used in the clinical treatment of various diseases
including kidney stones, obesity [14], cancer [15], and
Fig. 5 Alteration of cell membrane permeability by ATP/P2X7 contributed to the promotion of cell apoptosis of MTX by shock waves. a U2OS
cells were treated with the indicated concentrations of ATP and cell viability was assessed by MTT assay. b U2OS cells were treated with MTX,
shock waves and KN62 as indicated and apoptosis was assessed. Shown are representative histograms. c Quantitation of the apoptosis rates.
Data are mean ± SD, n = 3, *p < 0.05,Student,s t-test
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burns [16]. Recently, shock waves have been used to
treat tendinitis, femoral head necrosis, and nonunion
fractures [17]. The aim of this work was to explore
whether shock waves can be used as an adjuvant therapy
for osteosarcoma. First, we investigated the shock wave
conditions that must be maintained to reduce over-
whelming cell disruption. We found that the majority of
cells could withstand shock wave treatments with <450
pulses at 7 kV or <200 pulses at 14 kV. Similar results
were obtained in MC3T3 cells.
Gambihler et al. previously reported that shock waves
could permeabilize plasma membrane of L1210 mouse
leukemia cells [18]. Using two fluorophores, Calcein and
LY, we investigated the effect of shock waves on the per-
meability of U2OS osteosarcoma cells. We found that
shock wave treatment significantly increased the uptake
of these dyes when compared to control cells that take
up a small quantity of fluorophore likely by fluid-phase
pinocytosis or other mechanisms [19]. In addition we
found that cells treated with higher shock wave intensity
absorbed more fluorophore than cells treated with lower
intensity. Based on these results, we hypothesized that
shock wave treatment would also increase the uptake of
MTX. Indeed, we found that shock wave treatment sig-
nificantly increased intracellular concentrations of MTX
and enhanced the cytotoxicity of MTX on U2OS osteo-
sarcoma cells.
Shock waves have been previously reported to stimu-
late the release of ATP into the extracellular compart-
ment by accelerating the fusion of ATP-rich vesicles
with the cell membrane [13] or by opening of cell mem-
brane channels [20–23]. By application of GdCl3 to
block channels and BFA to inhibit ATP production,
shock waves still elevated ATP levels, suggesting there
exists the third mechanism that the high-strength in-
stant positive phase pressure generated by shock wave
during a few seconds may cause a transient increase of
cell membrane permeability, leading to a burst of ATP
outflow. Our results demonstrate that shock wave-
induced release of ATP did not contribute to promotion
of cell death. Further experiments indicated that shock
waves significantly enhanced MTX-induced apoptosis,
which was however significantly reduced by inhibition of
P2X7 receptors. Our data suggest that release of ATP
Fig. 6 Shock waves significantly stimulated U2OS cell uptake of
Calcein and LY. The uptake of Calcein and LY following addition of
KN62 (10 μM for 5 min) were determined and significantly reduced
intake of Calcein and LY following addition of KN62 was observed.
Data are mean ± SD, n = 3, ***p < 0.05, Student’s t-test
Fig. 7 The proposed mechanism by which shockwave treatment increases osteosarcoma cell death: Shockwave promote the release of
intracellular ATP, which in turn binds P2X7 receptors that contribute to the opening of cell membrane channels that allow entrance of MTX into
cells,by which the osteosarcoma cell death increases
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and binding of ATP to P2X7 receptors contributes to
the opening of cell membrane channels to facilitate
uptake of MTX by cells, resulting in subsequent apop-
tosis. We thus speculate that shock waves promote the
release of intracellular ATP, which in turn binds P2X7
receptors that contribute to the opening of cell mem-
brane channels that allow entrance of macromolecules
into cells (Fig. 7).
Conclusions
In conclusion, shock waves promote U2OS cell uptake
of the chemotherapeutic drug MTX, and enhances
MTX-induced cytotoxicity. Shock waves induce ATP re-
lease and enhance MTX-induced apoptosis in a P2X7
receptor-dependent manner. Our findings suggest that
shock wave treatment may be a potential adjuvant ther-
apy for the control of osteosarcoma. Therefore, after
chemotherapy, osteosarcoma patients may be treated by
local tumor shock wave therapy to promote the uptake
of chemotherapy drugs by osteosarcoma cells. This strategy
may reduce the dosage of chemotherapy drugs, alleviate
side effects of chemotherapy drugs, but also improve the
treatment outcome of osteosarcoma.
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